Drug Profile
Research programme: coronavirus inhibitors - Takeda/USAMRIID
Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator United States Army Medical Research Institute of Infectious Diseases; ViroPharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Severe acute respiratory syndrome
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 12 May 2003 Preclinical trials in Severe acute respiratory syndrome in USA (unspecified route)